{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:56:37Z","timestamp":1740149797355,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s12328-021-01432-4","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T07:03:46Z","timestamp":1620889426000},"page":"1221-1226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Reactivation of hepatitis C virus with severe hepatitis flare during steroid administration for interstitial pneumonia"],"prefix":"10.1007","volume":"14","author":[{"given":"Kosuke","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1171-7835","authenticated-orcid":false,"given":"Jun","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Kakazu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akitoshi","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mio","family":"Tsuruoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Masamune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,13]]},"reference":[{"key":"1432_CR1","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00535-017-1427-x","volume":"53","author":"G Suda","year":"2018","unstructured":"Suda G, Ogawa K, Morikawa K, et al. Treatment of hepatitis C in special populations. J Gastroenterol. 2018;53:591\u2013605.","journal-title":"J Gastroenterol"},{"key":"1432_CR2","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/apt.14328","volume":"46","author":"M Lin","year":"2017","unstructured":"Lin M, Kramer J, White D, et al. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents. Aliment Pharmacol Ther. 2017;46:992\u20131000.","journal-title":"Aliment Pharmacol Ther"},{"key":"1432_CR3","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.jhep.2012.07.031","volume":"57","author":"P Mahale","year":"2012","unstructured":"Mahale P, Kontoyiannis DP, Chemaly RF, et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol. 2012;57:1177\u201385.","journal-title":"J Hepatol"},{"key":"1432_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/cid\/civ344","volume":"61","author":"S Kusumoto","year":"2015","unstructured":"Kusumoto S, Tanaka Y, Suzuki R, et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study. Clin Infect Dis. 2015;61:719\u201329.","journal-title":"Clin Infect Dis"},{"key":"1432_CR5","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.3748\/wjg.v17.i12.1531","volume":"17","author":"ML Manzano-Alonso","year":"2011","unstructured":"Manzano-Alonso ML, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol. 2011;17:1531\u20137.","journal-title":"World J Gastroenterol"},{"key":"1432_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3390\/v11050457","volume":"11","author":"J Inoue","year":"2019","unstructured":"Inoue J, Nakamura T, Masamune A. Roles of hepatitis B virus mutations in the viral reactivation after immunosuppression therapies. Viruses. 2019;11:457.","journal-title":"Viruses"},{"key":"1432_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver.","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370\u201398.","journal-title":"J Hepatol"},{"key":"1432_CR8","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u201399.","journal-title":"Hepatology"},{"key":"1432_CR9","doi-asserted-by":"publisher","first-page":"870","DOI":"10.5009\/gnl16434","volume":"11","author":"HL Lee","year":"2017","unstructured":"Lee HL, Bae SH, Jang B, et al. Reactivation of hepatitis C virus and its clinical outcomes in patients treated with systemic chemotherapy or immunosuppressive therapy. Gut Liver. 2017;11:870\u20137.","journal-title":"Gut Liver"},{"key":"1432_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/hep.29344","volume":"67","author":"HA Torres","year":"2018","unstructured":"Torres HA, Hosry J, Mahale P, et al. Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study. Hepatology. 2018;67:36\u201347.","journal-title":"Hepatology"},{"key":"1432_CR11","doi-asserted-by":"publisher","first-page":"ofv211","DOI":"10.1093\/ofid\/ofv211","volume":"3","author":"P Mahale","year":"2016","unstructured":"Mahale P, Thomas SK, Kyvernitakis A, et al. Management of multiple myeloma complicated by hepatitis C virus reactivation: the role of new antiviral therapy. Open Forum Infect Dis. 2016;3:ofv211.","journal-title":"Open Forum Infect Dis"},{"key":"1432_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.msard.2016.08.003","volume":"9","author":"A Tagawa","year":"2016","unstructured":"Tagawa A, Ogawa T, Tetsuka S, et al. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis. Mult Scler Relat Disord. 2016;9:155\u20137.","journal-title":"Mult Scler Relat Disord"},{"key":"1432_CR13","doi-asserted-by":"publisher","first-page":"6716","DOI":"10.3748\/wjg.v20.i22.6716","volume":"20","author":"O Yazici","year":"2014","unstructured":"Yazici O, Sendur MA, Aksoy S. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. World J Gastroenterol. 2014;20:6716\u201324.","journal-title":"World J Gastroenterol"},{"key":"1432_CR14","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.2169\/internalmedicine.53.3194","volume":"53","author":"N Mori","year":"2014","unstructured":"Mori N, Imamura M, Takaki S, et al. Hepatitis C virus (HCV) reactivation caused by steroid therapy for dermatomyositis. Intern Med. 2014;53:2689\u201393.","journal-title":"Intern Med"},{"key":"1432_CR15","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1177\/0961203315571465","volume":"24","author":"MH Chen","year":"2015","unstructured":"Chen MH, Chen MH, Tsai CY, et al. Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy. Lupus. 2015;24:1029\u201336.","journal-title":"Lupus"},{"key":"1432_CR16","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1053\/j.gastro.2010.02.004","volume":"138","author":"S Ciesek","year":"2010","unstructured":"Ciesek S, Steinmann E, Iken M, et al. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology. 2010;138:1875\u201384.","journal-title":"Gastroenterology"},{"key":"1432_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0192-0561(99)00005-3","volume":"21","author":"N Magy","year":"1999","unstructured":"Magy N, Cribier B, Schmitt C, et al. Effects of corticosteroids on HCV infection. Int J Immunopharmacol. 1999;21:253\u201361.","journal-title":"Int J Immunopharmacol"},{"key":"1432_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/hep.1840190203","volume":"19","author":"S Magrin","year":"1994","unstructured":"Magrin S, Craxi A, Fabiano C, et al. Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment. Hepatology. 1994;19:273\u20139.","journal-title":"Hepatology"},{"key":"1432_CR19","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1111\/liv.13685","volume":"38","author":"Y Asahina","year":"2018","unstructured":"Asahina Y, Itoh Y, Ueno Y, et al. Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection. Liver Int. 2018;38:1552\u201361.","journal-title":"Liver Int"},{"key":"1432_CR20","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/hepr.13546","volume":"50","author":"Y Asahina","year":"2020","unstructured":"Asahina Y, Liu CJ, Gane E, et al. Twelve weeks of ledipasvir\/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: integrated analysis of three clinical trials. Hepatol Res. 2020;50:1109\u201317.","journal-title":"Hepatol Res"},{"key":"1432_CR21","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1136\/gut.2004.048009","volume":"54","author":"MG Rumi","year":"2005","unstructured":"Rumi MG, De Filippi F, La Vecchia C, et al. Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut. 2005;54:402\u20136.","journal-title":"Gut"},{"key":"1432_CR22","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1365-2141.2010.08154.x","volume":"150","author":"V Pitini","year":"2010","unstructured":"Pitini V, Sturniolo G, Arrigo C, et al. HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. Br J Haematol. 2010;150:116\u20138.","journal-title":"Br J Haematol"},{"key":"1432_CR23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jiac.2016.12.008","volume":"23","author":"Y Kawano","year":"2017","unstructured":"Kawano Y, Miyanishi K, Takahashi S, et al. Hepatitis C virus reactivation due to antiemetic steroid therapy during treatment of hepatocellular carcinoma. J Infect Chemother. 2017;23:323\u20135.","journal-title":"J Infect Chemother"},{"key":"1432_CR24","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1002\/hep.510270629","volume":"27","author":"S Brambilla","year":"1998","unstructured":"Brambilla S, Bellati G, Asti M, et al. Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease. Hepatology. 1998;27:1678\u201386.","journal-title":"Hepatology"},{"key":"1432_CR25","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2169\/internalmedicine.53.2060","volume":"53","author":"N Yuki","year":"2014","unstructured":"Yuki N, Yoshioka A, Yasuda R, et al. Hepatitis C virus-associated neuropathy accompanied by eosinophilic vasculitis and granuloma formation. Intern Med. 2014;53:1187\u201390.","journal-title":"Intern Med"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01432-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-021-01432-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01432-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T17:43:33Z","timestamp":1699033413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-021-01432-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,13]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1432"],"URL":"https:\/\/doi.org\/10.1007\/s12328-021-01432-4","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"type":"print","value":"1865-7257"},{"type":"electronic","value":"1865-7265"}],"subject":[],"published":{"date-parts":[[2021,5,13]]},"assertion":[{"value":"2 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JI received research grants from Gilead Sciences and AbbVie GK. The other authors state that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Written consent was obtained from the patient to publish the clinical and virological findings.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}